[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stereotactic-body-radiation-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stereotactic-body-radiation-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,67,91,119,152,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100364058","oar-based-dose-escalated-sbrt-with-real-time-adaptive-mri-guidance-for-liver-metastases-100364058",false,"NCT04020276","OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases","A Phase I Study of OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases","Inclusion Criteria:\n\n* Have a diagnosis of histologically confirmed or clinically suspected metastatic cancer to the liver.\n* Participant must be a candidate for SBRT to at least one intrahepatic lesion but no more than 6 intrahepatic lesions.\n* Participant must be a candidate for treatment on the ViewRay treatment unit. Must be screened to rule out implants and devices that are not MRI compatible.\n* Be willing and able to provide written informed consent.\n* Participants may be therapy-naïve or have had prior systemic therapy up to two weeks prior to study entry.\n* No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet all of the following to be eligible:\n\n  * At least 28 days from prior definitive treatment of their CNS disease by surgical resection, SBRT or Whole Brain Radiation Therapy (WBRT) at the time of registration\n  * AND asymptomatic and off systemic corticosteroids and\u002For enzyme-inducing antiepileptic medications for brain metastases for \\>14 days prior to registration.\n* Demonstrate adequate organ function as defined in the following table; all screening labs should be performed within 28 days of SBRT treatment initiation.\n\n  * Platelet count greater than or equal to 50000 \u002FµL\n  * Absolute Neutrophil Count (ANC) greater than or equal to 1000 \u002FµL\n  * Hemoglobin (Hgb) greater than or equal to 8 g\u002FdL or greater than or equal to 5.6 mmol\u002FL without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)\n  * Serum creatinine OR measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) Creatinine\u002FCalculated creatinine clearance (CrCl) greater than or equal to 30 mL\u002Fmin for subject with creatinine levels greater than 1.5 X institutional upper limit of normal (ULN)\n  * Bilirubin greater than or equal to 1. 5 × ULN OR direct bilirubin greater than or equal to ULN for participants with total bilirubin levels greater than 1.5 ULN\n  * Aspartate aminotransferase (AST) and ALT (SGPT) greater than or equal to 5 × ULN\n  * International Normalized Ratio (INR) or Prothrombin Time (PT) greater than or equal to 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n  * Activated Partial Thromboplastin Time (aPTT) greater than or equal to 1.5 X ULN unless participant is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* For participants enrolled on the liver dose escalation arm, screening labs must be consistent with Child Pugh class A unless therapeutic anticoagulation places them in Child Pugh B. In that case, trial entry or exclusion will be at the discretion of the treating physician.\n* Have a performance status of 2 or less on the Eastern Cooperative Oncology Group (ECOG) performance scale.\n* Life expectancy of \\> 12 weeks.\n* Women of childbearing potential (WOCP) should have a negative urine or serum pregnancy test prior to initiation of radiation therapy. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* WOCP must not be pregnant or breast-feeding.\n* WOCP must be willing to use an effective method of birth control such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), use of a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence for the duration of the radiotherapy and 60 days thereafter.\n\nNOTE: A person of childbearing potential is anyone (regardless of sexual orientation, gender identity, having undergone a tubal ligation, or remaining celibate by choice) who was born with a uterus and at least one ovary and meets both of the following criteria:\n\n* Is post-menarcheal (i.e., has had at least one prior menses)\n* Has not undergone a hysterectomy or bilateral oophorectomy or has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n* Participant is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nExclusion Criteria:\n\n* Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the initiation of SBRT.\n* History of a second invasive cancer in the last 3 years (except for appropriately treated low-risk prostate cancer, treated non-melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast appropriately treated in situ\u002Fearly stage cervical\u002Fendometrial cancer.\n* Has an active infection requiring systemic therapy.\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Has known psychiatric or substance abuse disorders that would interfere with follow up scans or visits.\n* Has a primary tumor histology of germ cell tumor, leukemia, or lymphoma.\n* Has a primary liver cancer such as cholangiocarcinoma or hepatocellular carcinoma.\n* Has had prior radiation therapy that significantly overlaps with the liver.\n* Has a diagnosis of Crohn's disease, ulcerative colitis, or scleroderma.\n* Participants with Gilbert's disease or other primary disorders of bilirubin metabolism will not be allowed on the trial.\n* For participants in the liver dose escalation arm only, has pre-existing liver disease such that patients are classified as Child Pugh B or worse. If the participant is anti-coagulated such that their INR places them in the CP-B classification, exclusion or inclusion will be at the discretion of the treating physician.\n* Pregnancy or women of childbearing potential and men who are sexually active and refuse to use medically acceptable forms of contraception.\n* Participants with implanted hardware that would preclude MRIs.","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this trial is to identify a safe maximum tolerated dose level for MRI-guided Stereotactic Body Radiation Therapy (SBRT) treatment of bowel and liver metastases, respectively.\n\nEligible participants will be on study for up to 12 months.",[26,27,28],"Liver Metastases","Stereotactic Body Radiation Therapy","MRI-guided Treatment","RECRUITING","2026-06-09",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":33},"2019-11-04",{"date":37,"type":20},"2028-12",{"name":39,"class":40},"University of Wisconsin, Madison","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100618697","impact-of-a-hypnotic-recording-on-artifacts-in-4d-ct-in-the-context-of-stereotactic-body-radiation-therapy-for-lung-cancer-100618697","NCT07334990","Impact of a Hypnotic Recording on Artifacts in 4D CT in the Context of Stereotactic Body Radiation Therapy for Lung Cancer","HYPNOCT-4D","Inclusion Criteria:\n\n* Age ≥18 years,\n* Indication for lung SBRT, peripheral or central lesion,\n* Patient new to hypnosis (medical or stage hypnosis),\n* Patient covered by social security or equivalent,\n* Dated and signed consent form.\n\nExclusion Criteria:\n\n* Indication for treatment with abdominal compression,\n* Patient undergoing treatment for multiple lesions in the same treatment sequence,\n* Patient with an ultra-central lesion (distance to the mediastinum \\\u003C 2 cm),\n* Patient already included in this protocol,\n* Cognitive or physical disorders preventing the trial from proceeding smoothly,\n* Patient with one or more active psychotic disorders (such as schizophrenia),\n* Patients suffering from severe dissociative disorders,\n* Patient who does not understand French or is deaf,\n* Pregnant or breastfeeding women,\n* Patient under guardianship or curatorship or deprived of liberty.",{"count":50,"type":20},25,[23],"This is a single-center prospective cohort study evaluating the impact of a simple audio recording hypnosis system on the occurrence of artifacts on 4D CT scans in patients requiring SBRT radiotherapy for lung lesions (peripheral or central).\n\nThe primary objective of the study is to evaluate the use of a hypnotic recording on the reduction of artifacts in 4D CT scans for patients undergoing stereotactic body radiation therapy for lung cancer.\n\nThe secondary objectives are to evaluate:\n\n* the impact of hypnotic recording on the reduction of artifacts on intrathoracic structures (trachea, main bronchi, diaphragm, lesions, heart, and lungs),\n* the regularity of respiratory amplitude,\n* the regularity of respiratory rate,\n* the volume of Internal Target Volume (ITV),\n* the reproducibility of ITV volume,\n* patient satisfaction.\n\n  1. Before this dosimetric scan, the patient will complete a self-administered questionnaire on anxiety: the HADS-A questionnaire (Hospital Anxiety and Depression Scale-only questions relating to anxiety).\n\n     During this examination, the MERM explains the dosimetric scan procedure to the patient. After the immobilization system has been set up in accordance with the department's standard protocol, a 4D CT scan will be performed while asking the patient to breathe regularly. In the event of an artifact at the level of the lesion, a second 4D CT scan will be performed under the same conditions.\n  2. The hypnotic audio recording will be played through the room's speakers. The hypnotic recording is structured in three stages, with a 5-minute induction phase, a 5-minute working phase, and finally a 5-minute return phase.\n\n     After 5 minutes of playback, the 4D CT scan for the study is performed using the same acquisition parameters as the free 4D CT scan.\n  3. Following the first radiotherapy session and for all patients included in the study, a 4D dosimetric scan will be performed using the hypnotic recording again, as described above, in order to assess the inter-fraction reproducibility of the ITV volume.\n\nFollowing this second 4D CT scan under hypnosis, patient satisfaction will be assessed (using a Likert scale questionnaire).",[27,54],"Lung Lesions",[56],"Hypnosis","NOT_YET_RECRUITING","2026-01-06",{"date":60,"type":33},"2026-01-12",{"date":62,"type":20},"2025-12-30",{"date":64,"type":20},"2027-01-30",{"name":66,"class":40},"Centre Leon Berard",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100453785","safety-and-efficacy-of-sbrt-in-the-reirradiation-for-ultra-central-thoracic-malignant-tumors-100453785","NCT05189054","Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors","Inclusion Criteria:\n\n* Pathological diagnosis is malignant tumor.\n* The location of the target lesion belongs to the ultra-central type of chest.\n* The target lesion had a history of radiotherapy, and the lesion diameter is ≤ 5cm.\n* There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.\n* KPS\\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.\n\nExclusion Criteria:\n\n* Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.\n* The general condition is poor, and the expected survival time is less than 3 months.\n* Psychiatric patients or poor compliance, unable to cooperate to complete treatment.\n* For other reasons, the researcher believes that it is not suitable to participate in this trial.","80 Years",{"count":75,"type":20},40,"OBSERVATIONAL","The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for \"ultral-central\" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.",[27,79,80,81],"Irradiation; Reaction","Thoracic Tumor","Recurrent Cancer","2023-12-22",{"date":84,"type":33},"2023-12-27",{"date":86,"type":33},"2022-05-01",{"date":88,"type":20},"2027-04-30",{"name":90,"class":40},"Peking University Third Hospital",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":73,"enrollmentInfo":99,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100401868","comparison-of-efficacy-in-sbrt-of-large-hcc-with-or-without-tace-100401868","NCT04512846","Comparison of Efficacy in SBRT of Large HCC With or Without TACE","Comparison of Efficacy in Stereotactic Body Radiation Therapy (SBRT) of Large Hepatocellular Carcinoma (5-10 cm) With or Without Transcatheter Arterial Chemoembolization (TACE)","Inclusion Criteria:\n\n* primary HCC diagnosed by a surgeon and\u002For radiologist and oncologist according to the international guidelines for the management of HCC or by pathology\n* single lesion and longest tumor diameter were 5-10cm;\n* CP-A or B classification;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1;\n* distances between tumor and normal organs (esophagus, stomach, duodenum, bowel) are more than 5 mm\n* unsuitable for other therapies, such as patients with heart disease, uncontrolled diabetes, uncontrolled hypertension, etc.\n* rejecting other therapies such as resection, liver transplantation, etc.\n* platelet count≥50 × 109\u002FL, white blood count≥1.5 × 109\u002FL;\n* patients infected with hepatitis B virus who are treated with adefovir or entecavir; patients infected with hepatitis C virus whose HCV DNA are negative.\n\nExclusion Criteria:\n\n* tumor thrombus;\n* lymph node involvement;\n* extrahepatic metastasis.","30 Years",{"count":100,"type":20},100,"The study aims to compare efficacy and adverse reactions of large hepatocellular carcinoma participants (5-10cm) who receive stereotactic body radiation therapy with or without transcatheter arterial chemoembolization.The investigators will optimize the combined treatment schedule of SBRT for hepatocellular carcinoma participants by comparing overall survival rates, progression-free survival rates and local control and adverse reaction occurrence rates in the two groups.",[103,27,104],"Large HCC Patients","Transcatheter Arterial Chemoembolization",[106,107,108,109],"CyberKnife","SBRT","large HCC","prognosis","2023-06-24",{"date":112,"type":33},"2023-06-27",{"date":114,"type":33},"2020-08-01",{"date":116,"type":20},"2026-08-30",{"name":118,"class":40},"Beijing 302 Hospital",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":127,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100455338","start-met-hs-prostate-cancer--sbrt--androgen-receptor-therapy-metastatic-hspc-100455338","NCT05209243","START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC","Phase III Study of Stereotactic Body Radiation Therapy (SBRT) Plus Standard of Care in Castration Sensitive Oligometastatic Prostate Cancer Patients.","START-MET","Inclusion Criteria:\n\n1. Patients with a histological diagnosis of prostate cancer.\n2. Castration sensitive prostate cancer patients.\n3. Oligometastatic disease defined as less than or equal 3 lesions based on CT and Bone Scan and less than or equal 5 lesions based on Choline or PSMA PET\u002FTC. Bone metastases (including the spine) or\u002Fand lymph nodes metastases.\n4. Informed consent is obtained from the patient.\n5. Adequate bone-marrow, liver and renal function:\n\n   * Haemoglobin ≥10 g\u002FdL, Leucocytes ≥ 2000\u002Fmm\\^3, Neutrophils ≥1500\u002Fmm\\^3, platelets ≥1000007mm\\^3\n   * GOT, GPT and Total Bilirrubin ≤1.5\\*ULN (Upper limit of normality)\n   * Creatinine ≤1.5\\*ULN or Creatinine Clearance ≥50 ml\u002Fmin\\^-1\n\nExclusion Criteria:\n\n1. Lack of a histological diagnosis of prostate cancer.\n2. Castration resistant prostate cancer patients according to PCWG3\\[30\\].\n3. Metastatic disease defined as greater than or equal 3 lesions based on CT and Bone Scan and greater than or equal 5 lesions based on Choline or PSMA PET\u002FTC.\n4. Visceral metastases.\n5. Tumor stage T4 according to AJCC 8th Edition Cancer staging form.\n6. Prior treatment with docetaxel, second generation hormonal treatments (Apalutamide\u002FAbiraterone+Prednisone\u002FEnzalutamide) or bone antiresorptive therapy.\n7. Presence of symptoms or signs that are indicative of urgent surgery\u002Fradiotherapy as the first treatment for the metastases disease.\n8. Lesions that require SBRT treatment that exceed critical organ tolerance limits, or do not meet the criteria for the prescription of SBRT techniques used.\n9. History of another neoplastic pathology which is not a currently controlled with the exception basal cell carcinomas.\n10. Presence of a cardiopathy or metabolic disorder that does not recommend the treatment with second generation hormonal treatments, or the presence of inflammatory bowel disease or other pathology that does not recommend the treatment with radiotherapy.\n11. Lack of informed consent or the patient's ability to give consent.\n12. Participation in other clinical trials at the time of inclusion or in the 3 previous months.","MALE",{"count":129,"type":20},266,[23],"Phase III study of stereotactic body radiation therapy (SBRT) plus standard of care in castration sensitive oligometastatic prostate cancer patients, defined as androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients and second generation hormonal treatments (Apalutamide\u002FAbiraterone+Prednisone\u002FEnzalutamide) vs androgen deprivation therapy plus radiotherapy to the primary tumor in previously not treated patients plus second generation hormonal treatments, for the treatment of oligometastatic prostate cancer.",[133,27],"Prostate Cancer",[107,135,136,137,138,139,140,141],"Prostate cancer","Metastatic hormonosensitive prostate cancer","Second generation hormonal treatments","Oligometastatic prostate cancer","Apalutamide","Enzalutamide","Darolutamide","2023-05-18",{"date":144,"type":33},"2023-05-19",{"date":146,"type":33},"2023-01-26",{"date":148,"type":20},"2027-01",{"name":150,"class":40},"Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic",2,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100470895","the-ctdna-for-evaluating-whether-to-use-adjuvant-therapy-after-sbrt-in-patients-with-early-lung-cancer-100470895","NCT05411809","The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer","Inclusion Criteria:\n\n1. Patients pathologically diagnosed as non-small cell lung cancer, and was early stage（AJCC 8th）;\n2. Patients aged between 18 -80 years; with expected survival time\\>3 months.\n3. Patients with normal organ function within 30 days prior to treatment, the following criteria are met:\n\n   1. blood routine examination criteria : i) hemoglobin (HB) ≥90g\u002FL; ii) absolute neutrophil count (ANC) ≥1.5×10e9\u002FL; iii) platelet (PLT) ≥80×10e9\u002FL; b) biochemical tests meet the following criteria: i) total bilirubin (TBIL) ≤1.5 times of upper limit of normal (ULN); ii) alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 ULN; iii) serum creatinine (Cr) ≤1.5 ULN or creatinine clearance (CCr) ≥60mL\u002Fmin;\n\nExclusion Criteria:\n\n1. Patients with small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer);\n2. Patients with factors that affect oral medication (such as cannot swallow, chronic diarrhea and intestinal obstruction, etc.) or intravenous medication;\n3. Patients with any other severe and\u002For uncontrolled disease;\n4. Patients with a history of psychotropic medicine abuse and cannot quit or have mental disorders;\n5. Patients with disease which will severely endanger their security and could not complete this study, according to the judgement of researchers；",{"count":159,"type":20},180,[23],"The purpose of this study is to determine whether ctDNA could help to evaluate whether to use drug adjuvant therapy after SBRT in patients with early lung cancer.",[27],"2022-06-06",{"date":165,"type":33},"2022-06-09",{"date":167,"type":20},"2022-06-15",{"date":169,"type":20},"2027-05-15",{"name":90,"class":40},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":179,"conditions":180,"keywords":184,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":41},"100305234","prospective-observational-trial-to-evaluate-quality-of-life-after-stereotactic-ablative-radiation-therapy-in-patients-with-hepatocellular-carcinoma-100305234","NCT03253536","Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma","LIVERCARE","Inclusion Criteria:\n\n* histologically or radiologically proven hepatocellular carcinoma\n* 1-3 lesions suitable for stereotactic radiation therapy\n* indication for SBRT according to multidisciplinary board evaluation\n* age \\>= 18 years\n* written informed consent for study participation\n* mental and verbal ability to complete standardized questionaires according to assessment by investigator (physician)\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* prior HCC specific systemic therapy\n* concurrent oncological systemic treatment\n* distant metastases\n* inadequate ability tobe compliant with the protocol or to complete standardizes questionaires\n* inability to receive contrast-enhanced planning CT\n* missing ability to give informed consent\n* legal custody",{"count":100,"type":20},"Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points during routine follow-up.",[181,182,27,183],"Hepatocellular Cancer","Quality of Life","Observational",[181,182,185,186],"stereotactic body radiation therapy","observational","2017-08-16",{"date":189,"type":33},"2017-08-18",{"date":191,"type":33},"2017-07-10",{"date":193,"type":20},"2027-07-10",{"name":195,"class":40},"Ludwig-Maximilians - University of Munich"]